July 2022 - Page 6 of 21

MondayJul 25, 2022 12:42 pm

QualityStocksNewsBreaks – DPCM Capital Inc.’s (NYSE: XPOA) Pending SPAC Merger Target D-Wave Forms Alliance with Mastercard (NYSE: MA) to Champion Quantum Computing Solutions

DPCM Capital (NYSE: XPOA) recently entered into a definitive transaction agreement with D-Wave Systems Inc., whereby, upon closing of the transaction, shares of the pending parent company – D-Wave Quantum Inc. – are expected to trade on the NYSE under ticker symbol QBTS. D-Wave Systems, a leader in quantum computing systems, software and services, and the only company building both quantum annealing and gate-based quantum computers, and Mastercard (NYSE: MA) recently announced a multi-year strategic alliance to champion the acceleration and adoption of quantum computing solutions. According to the announcement, D-Wave and Mastercard will collaborate on the research and development…

MondayJul 25, 2022 12:16 pm

QualityStocksNewsBreaks – Correlate Infrastructure Partners Inc. (CIPI) Signs LOI to Acquire Leading Solar, Storage Platform

Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean-energy solutions provider for North America, has entered into a nonbinding letter of intent (“LOI”) outlining its plans to acquire a top-10 solar, battery storage and roofing provider based in California. According to the announcement, the target company focuses on sales and self-performance construction of solar and roofing services for residential and commercial properties; CIPI anticipates the acquisition to be complete and accretive by the second half of this year, marking the “next evolution” of the company as a community-scale distributed energy company. Highlights of the agreement include expanded national…

MondayJul 25, 2022 12:04 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, July 27, 2022. Proposals include the authorization to increase the number of shares available for issuance by the company and the authorization for the board of directors to effect a reverse stock split of the outstanding shares of the company’s common stock, at a split…

MondayJul 25, 2022 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Notice of Allowance of 26th Worldwide Patent

Lexaria, a global innovator in drug delivery technology, has developed the patented DehydraTECH(TM) technology which has been the subject of several issued patents Recently, Lexaria reported it had been notified of the allowance of its 26th worldwide patent with a new patent to be granted in Japan The patent is the fourth to be granted in Japan and the first patent issued from Lexaria’s seventh patent family Lexaria also submitted a briefing book to the FDA to facilitate its upcoming pre-Investigational New Drug (“IND”) meeting with the agency “We are extremely pleased to have received our first patent protecting our…

MondayJul 25, 2022 11:52 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed…

MondayJul 25, 2022 11:22 am

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Launches Revamped ‘Song of the Summer’ Contest

Friendable (OTC: FDBL), a mobile technology and marketing company, today announced its “Song of the Summer” contest and artist promotion. According to the update, the submission process opened to artists last week as the company received an immediate positive response with entries pouring in. The contest registration will remain open until July 31, 2022, and fan voting will begin in August 2022 to determine each of the five winners per genre. “This contest has been a highly sought after and anticipated promotion since it began with the former Artist Republik management team,” said Friendable CEO Robert A. Rositano Jr. “Now…

MondayJul 25, 2022 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company that focuses on fusing traditional therapeutics with psychedelic research, recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage…

MondayJul 25, 2022 10:30 am

Correlate Infrastructure Partners Inc. (CIPI) Helps Clients Realize ESG Strategies Through Comprehensive Energy Analysis and Environmentally Friendly Upgrades to Facilities

Nearly a decade has passed since approximately 200 government entities met in Paris, ratifying a binding agreement to work toward reducing pollution and its negative impacts on global climate Louisiana-based Correlate Infrastructure Partners is helping to educate corporate clients on both the affordability and potential profit offered by ESG solutions that reduce their greenhouse gas impact CIPI’s Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design) subsidiaries provide related help on acquisitions and project development, as well as resource financing A recent report by consulting firm McKinsey & Company forecasts growing adoption of renewable energy solutions by the public,…

MondayJul 25, 2022 9:45 am

Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Charges Ahead as Clean Tech Company on the Right Track to Providing Optimal Inverter Technology

Hillcrest announces AGM results; all seven members of Board of Directors are re-elected while new board chair David Farrell is appointed Company exits fossil-fuel business and completes transition to clean tech market where it continues to develop inverter technology empowering next generation of more efficient and powerful electric vehicles Hillcrest reaches key milestone as it completes proof of concept testing of its inverter technology, with the commercial prototype soon to be available in Q4 2022 Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA), a Canadian cleantech company developing technologies for innovative electrical solutions such as powertrains and grid-connected renewable…

MondayJul 25, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine months The pivotal study was designed with four primary objectives Cybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the company’s proprietary CYB004 substance (https://ibn.fm/2Ab0T). Information from the study is expected to help the company accelerate by up to nine months its clinical development pathway of CYB004. “With the closing of this transaction…

Site Search

Company Search

Month: July 2022